We report a prospective pilot of GI Genius ColonPro 4.0 (Medtronic, Minneapolis, MN), the first FDA-approved computer-aided quality (CAQ) platform for colonoscopy.

Nebokitug (CM-101) is an anti-CCL24 monoclonal antibody with anti-inflammatory and anti-fibrotic properties. This phase 2 study evaluated the safety, tolerability, and biological activity of nebokitug in patients with primary sclerosing cholangitis (PSC).

Invasive fungal infections (IFIs) in acute-on-chronic liver failure (ACLF) are associated with transplant de-listings, high morbidity, and mortality. Optimal strategy of antifungal therapy in this setting remains uncertain. We compared suspicion-based (empirical) with investigation-driven (diagnostic/biomarker-driven-pre-emptive) antifungal therapy among ACLF patients in a high-burden setting.

Gluten-free diet (GFD) adherence is critical for individuals with celiac disease (CD) but is often hindered by food labeling inconsistencies and limited dietary support.

To determine the appropriate post-polypectomy colonoscopy surveillance interval, endoscopists synthesize information from colonoscopy and pathology report impressions and subsequently apply guideline-recommended interval algorithms, such as those developed by the United States Multi-Society Task Force (USMSTF). Given the complexity of these guidelines, this manual process is error-prone, necessitating automated tools, including large language models (LLMs), to improve guideline adherence.

Ulcerative colitis (UC) disease assessment considers both mucosal healing and symptoms which can disagree. We compared the artificial intelligence (AI) endoscopic cumulative disease score (CDS) to the Mayo endoscopic score (MES) for agreement with symptoms and health related quality of life (HR-QoL) in UC.

Fragmentomic analysis of blood-derived cell-free DNA (cfDNA) has emerged as a promising approach for cancer screening. We aimed to develop a novel cfDNA-based blood test and evaluate its diagnostic performance for colorectal cancer (CRC) and advanced adenoma (AA).

Long-term risk of acute pancreatitis (AP) and pancreatic cancer (PC) with mildly elevated lipase (MEL) is not well established.

Financial toxicity, the combined objective burden and subjective distress that affects patients' medical care, is not well described in patients with IBD. We aimed to characterize financial toxicity in patients with IBD.

Individuals with alcohol-associated liver disease (ALD) have low engagement in alcohol use disorder (AUD) treatment. This study aimed to identify barriers and facilitators to AUD treatment in ALD patients and provide recommendations to improve recognition of need, treatment initiation, and care continuation.

Irritable bowel syndrome (IBS) is a common, chronic disorder of gut-brain interaction (DGBI) that is characterized by core clinical features of abdominal pain and altered bowel movements. Because IBS remains defined by symptom patterns, most clinical care for patients with IBS relies on treatments directed by IBS subtype. Although the biopsychosocial model has advanced DGBI research and clinical care, and the current Rome IV criteria have greatly helped the diagnostic paradigm for IBS, the model does not identify specific pathophysiological mechanisms that operate in any one patient. Consequently, most interventions for IBS benefit only subsets of patients, and patients often progress through a series of 'trial and error' approaches to manage their IBS symptoms. There is a major clinical need to develop a practical basis for a personalized medicine approach in IBS care. In this article, we discuss how clinicians may incorporate additional clinical features and actionable biomarkers to better inform the initial choice of therapy for patients with IBS. Ideally, such a mechanistic approach should be more efficient, and ultimately more effective, leading to improved patient satisfaction and clinical outcomes.

Bowel urgency (BU) is a prevalent and highly burdensome symptom among patients with inflammatory bowel disease. While BU is now recognized as a key symptom of ulcerative colitis (UC), in the case of Crohn's disease (CD), it is often underrecognized by healthcare providers (HCPs) and inadequately captured in clinical assessments. Reported in up to 96% of patients with CD, BU can significantly impair quality of life, contributing to anxiety, social withdrawal, and reduced daily functioning. Despite its frequency and impact, BU is excluded from widely used CD activity indices and is infrequently included in clinical trial endpoints. An important challenge in the management of CD is the differing perceptions between patients and HCPs regarding the impact and importance of BU. This disconnect between patients and HCPs may lead to gaps in treatment and unmet patient needs. This narrative review synthesizes recent evidence on the prevalence, clinical significance, and underlying mechanisms of BU in CD. We also examine its impact on quality of life, evaluate current assessment tools, and highlight therapeutic approaches and gaps in HCP-patient communication. Greater awareness and systematic evaluation of BU as a multidimensional symptom of CD are critical for optimizing care and aligning clinical management with patient priorities.

Patients with autoimmune hepatitis (AIH) may have impaired quality of life and symptoms of depression and anxiety. Little is known about the long-term risk for psychiatric disorders. We conducted a population-based follow-up study on the risk of psychiatric disorders in patients with AIH and compared with the general population.

The ulcerative colitis (UC) to Crohn's disease (CD) incidence ratio varies across geography and time.

Large language models (LLMs) are increasingly used in clinical decision-making, but their role in appropriateness-based indications is uncertain.

Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disease of pregnancy, varying in incidence based on population and associated with adverse outcomes. We assessed the prevalence and outcomes of ICP categories defined by the 2023 EASL guidelines in a diverse U.S. population.